Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress

Executive Summary

In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.

You may also be interested in...



AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi

Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.

AstraZeneca Gets Fast Imfinzi Review For SCLC

The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel